Prominent publications by Omar Hasan Ali

KOL Index score: 8185

Prognosis of metastatic melanoma improved with the development of checkpoint inhibitors. The role of tumor infiltrating lymphocytes (TILs) in lymph node metastases of stage III melanoma remains unclear. We retrospectively characterized TILs in primary melanomas and matched lymph node metastases (stage III melanoma) of patients treated with the checkpoint inhibitor ipilimumab. Tumor infiltrating lymphocytes were characterized for CD3, CD4, and CD8 expressions by immunohistochemistry. 4/9 ...

Known for Lymph Node |  Tumor Infiltrating |  Melanoma Patients |  Response Ipilimumab |  Checkpoint Inhibitors
KOL Index score: 5936

BACKGROUND: Anti-programmed cell death protein 1 (PD1)/programmed death-ligand 1(PD-L1) therapy frequently entails immune-related adverse events (irAEs), and biomarkers to predict irAEs are lacking. Although checkpoint inhibitors have been found to reinvigorate T cells, the relevance of autoantibodies remains elusive.

OBJECTIVE: Our aim was to explore whether IgG autoantibodies directed against coexpressed antigens by tumor tissue and healthy skin correlate with skin irAEs and therapy ...

Known for Checkpoint Inhibitors |  Cell Lung |  Skin Iraes |  Death 1 |  Patients Baseline
KOL Index score: 5438

BackgroundLong-term survival of stage IV melanoma patients has improved significantly with the development of immune checkpoint inhibitors (CIs). Reliable biomarkers to predict response and clinical outcome are needed.MethodsWe investigated the role of melanoma-associated antibodies as predictive markers for CI therapy in two independent cohorts. In cohort 1, a prospective study, we measured specific antibodies before treatment, after one week and after six to nine weeks of treatment. ...

Known for Melanoma Patients |  Antibodies Monoclonal |  Response Survival |  Reliable Biomarkers |  Immune Checkpoint Inhibitors
KOL Index score: 5038

Immune checkpoint inhibitors have led to considerable therapy improvement in cancer patients. Autoimmune side effects including skin reactions are frequently observed. In melanoma, those include rash and vitiligo and were shown to be associated with a prolonged overall survival. Little is known about skin reactions in non-small cell lung cancer (NSCLC) patients during immunotherapy. Here, we retrospectively investigated immune-related adverse skin reactions (irAEs) in 40 patients with ...

Known for Skin Reactions |  Patients Nsclc |  Cell Lung |  Tumor Responses |  Immune Checkpoint Inhibitors
KOL Index score: 2306

Pruritus is associated with various skin diseases, dry skin, and with it an impaired skin barrier function. The study objective was to investigate short-term and long-term effects of two emollients on symptoms and skin barrier functions in xerotic eczema. Randomized, double-blind, study enrolling females/males, with bilateral itching. Two emollients, containing lactic acid and refined almond oil with/without polidocanol were administered on left versus right body sides. Itching severity, ...

Known for Itching Severity |  Dry Skin |  Publication Administration |  Eczema Emollients |  Barrier Function
KOL Index score: 2258

PURPOSE: Characterize ocular adverse events (oAEs) caused by immune checkpoint inhibitors (ICIs).

METHODS: Retrospective analysis of 41,674 cancer patients in the FDA Adverse Event Reporting System (FAERS) pharmacovigilance database receiving anti-PD-1/PD-L1, anti-CTLA-4, or anti-PD-1+ anti-CTLA-4 combination. Reporting odds ratio (ROR) was used to approximate oAE rate across regimens and indications.

RESULTS: The most common indications were lung cancer (27.3%) and melanoma (22.7%); ...

Known for Immune Checkpoint Inhibitors |  Lung Cancer |  Adverse Event |  Pd1 L1 |  Methods Retrospective
KOL Index score: 184

Background: Prognosis of metastatic non-small cell lung cancer significantly improved with the availability of checkpoint inhibitors (anti-PD-1/PD-L1). Unfortunately, reliable biomarkers to predict treatment benefit are lacking.

Patients and methods: We prospectively collected clinical and laboratory data of 56 non-small cell lung cancer patients treated with a checkpoint inhibitor. The aim was to identify baseline parameters correlating with worse outcome and to create a risk score that ...

Known for Checkpoint Inhibitors


Omar Hasan Ali: Influence Statistics

Sample of concepts for which Omar Hasan Ali is among the top experts in the world.
Concept World rank
iraes 04 #9
patients iciinduced hepatitis #10
occurrence iciinduced hepatitis #10
iciinduced hepatitis iraes #10
occurrence ici #10
iraes iciinduced hepatitis #10
occurrence prospective cohort #11
collagens programmed #13
skin coexpress bp180 #13
skinspecific igg #13
patients hepatitis cohort #14
immunological autoantigens #15
iciinduced hepatitis #15
iraes organs #15
nsclc skin #16
bp180specific igg #16
diseases nsclc #18
baseline therapy response #19
results40 patients #19
organs iraes #20
putatively factors #23
associations ici #25
alleles ici #25
iraes skin #27
coexpressed antigens #28
survival checkpoint inhibitors #29
igg nsclc #30
ici hepatitis #31
kantonsspital gallen #35
04 therapy #35
skin iraes #42
iraes checkpoint inhibitors #42
itching severity #49
iraes therapy #51
nsclc patients baseline #51
skin adverse events #58
pruritus survival #62
iraes biomarkers #82
bp180 specific #86
40 recruited #89

Key People For Checkpoint Inhibitors

Top KOLs in the world
Jedd D Wolchok
advanced melanoma tumor immunity nivolumab ipilimumab
Frank Stephen Hodi
advanced melanoma brain metastases nivolumab ipilimumab
Julie Renee Brahmer
lung cancer small cell advanced nsclc
Caroline Robert
advanced melanoma braf v600 advisory consultancy
Dirk Schadendorf
melanoma patients advisory consultancy braf v600
Drew M Pardoll
tumor cells prostate cancer inbred balb mice

Omar Hasan Ali:Expert Impact

Concepts for whichOmar Hasan Alihas direct influence:Checkpoint inhibitors,  Skin reactions,  Therapy response,  Cell lung,  Melanoma patients,  Iciinduced hepatitis,  Small cell,  Immune checkpoint inhibitors.

Omar Hasan Ali:KOL impact

Concepts related to the work of other authors for whichfor which Omar Hasan Ali has influence:Immune checkpoint inhibitors,  Cell lung,  Patients iraes,  Sensitive skin,  Clinical benefit,  Metastatic melanoma,  Checkpoint blockade.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Institute of Immunobiology, Kantonsspital St. Gallen, Rorschacher Strasse 95, 9007, St. Gallen, Switzerland | Department of Dermatology, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland | Institute for Immunobiology, Kantonsspit

FREE Custom List